Share
A global health organisation and state-of-the-art laboratory at The University of Queensland are collaborating to support the development and evaluation of point-of-care diagnostics for malaria with new custom-made proteins.
PATH and UQ’s Protein Expression Facility will supply researchers with malaria proteins to improve point-of-care diagnostic tools and help reduce the burden of malaria, which continues to affect more than 200 million people and cause more than 400,000 deaths each year.
Director of UQ’s Protein Expression Facility Professor Linda Lua said the partnership would help malaria researchers develop new diagnostic tools.
“New tools to enable the development of highly sensitive diagnostics are urgently needed to reduce disease and death attributable to malaria,” Professor Lua said.
Tuesday, 23 February 2021, 1:10 pm
AUCKLAND: COVID-19 Vaccine Corporation (CVC) has joined
forces with the University of Queensland in its vaccine
production efforts.
After halting development of its
spike protein based candidate in December, CVC continues to
progress development of its proprietary T-cell
vaccine.
Its T-cell vaccine is designed to work with
other existing vaccines in order to improve efficacy,
lengthen immunity time and to protect against all new
variants for the SARS-Cov-2 virus, including those from
Britain and South Africa.
CVC’s efforts and new
partnership are particularly timely in the wake of South
African government’s attempt to recall a million doses of
Press Release – COVID-19 Vaccine Corporation AUCKLAND: COVID-19 Vaccine Corporation (CVC) has joined forces with the University of Queensland in its vaccine production efforts. After halting development of its spike protein based candidate in December, CVC continues to progress development …
AUCKLAND: COVID-19 Vaccine Corporation (CVC) has joined forces with the University of Queensland in its vaccine production efforts.
After halting development of its spike protein based candidate in December, CVC continues to progress development of its proprietary T-cell vaccine.
Its T-cell vaccine is designed to work with other existing vaccines in order to improve efficacy, lengthen immunity time and to protect against all new variants for the SARS-Cov-2 virus, including those from Britain and South Africa.
Community Scoop » COVID-19 Vaccine Corporation Partners With The University Of Queensland scoop.co.nz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from scoop.co.nz Daily Mail and Mail on Sunday newspapers.